Protective Effects of Saxagliptin (And Vitamin D3) on Cell Function in Adult-onset Latent Autoimmune Diabetes

  • End date
    Jun 18, 2021
  • participants needed
  • sponsor
    Second Xiangya Hospital of Central South University
Updated on 18 August 2019
Zhiguang Zhou, Professor
Primary Contact
The Northern Jiangsu People's Hospital (2.0 mi away) Contact
+38 other location
autoimmune diabetes
glutamic acid


The main purpose of this study is to evaluate whether saxagliptin or (and vitamin D3) with metformin (and insulin) therapy can better protect islet cell function than metformin(and insulin) .


LADA is actually a form of type 1 diabetes, which is caused by autoimmune damage of islet cells and triggered by environmental factors based on genetic susceptibility. LADA shows some characteristics of type 2 diabetes at its onset, which develops slowly and latent, and easily be misdiagnosed as type 2 diabetes due to slowly cell function deterioration. This is a multi-center, open- label, 1:1:1 randomized controlled trial to investigate the protective effects of saxagliptin and vitamin D3 in LADA patients. The study comprises the 0-6weeks of screening period and the 104-week intervention period. After obtaining the informed consentthe screening will find out the eligible patients according to the inclusion/exclusion criteria, then the patients will be randomized to the 104-week intervention period. Subjects will be randomized into one of the three groups(arms) through central dynamic randomization: metformin (and insulin), metformin(and insulin) +saxagliptin, metformin(and insulin) +saxagliptin+vitamin D3. Our previous randomized- controlled pilot study showed that dipeptidyl peptidase 4 (DPP-4) inhibitors could significantly improve islet -cell function in patients with LADA. The main purpose of this study: To evaluate whether saxagliptin (and vitamin D3) with metformin (and insulin) therapy can better protect islet cell function than metformin (and insulin).

Treatment insulin, Metformin, Saxagliptin, Vitamin D3
Clinical Study IdentifierNCT02407899
SponsorSecond Xiangya Hospital of Central South University
Last Modified on18 August 2019

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Gender: Male or Female
Do you have Insulin dependent diabetes mellitus?
Volunteer to participate in the study with informed consent
The LADA patients to be included in this study are defined as
(1) Meet the 1999 WHO Diagnostic Criteria for Diabetes Mellitus; (2) Age at
diagnosis of DM 18 years old; (3) Glutamic acid decarboxylase antibody (GADA)
positive; (4) Serum fasting C-peptide 100 pmol/L or 2-hour postprandial
C-peptide 200 pmol/L; 3. Age between 18-70 years old; 4. Diabetes duration <4
year; 5. Outpatient or inpatient

Exclusion Criteria

Pregnancy, breastfeeding or planned pregnancy within two years
Gestational diabetes mellitus or other specific types of diabetes
Allergic to saxagliptin, vitamin D3 and their excipient
Treatment with any anti-diabetic medication other than insulin in the last 8 weeks prior to randomization
Use of systemic corticosteroids therapy (oral, intravenous) continuously for more than 7 days over the past 6 months
Treatment with cytochrome P450 3A4/5 (CYP450 3A4/5) inhibitor
Alanine aminotransferase (ALT) or aspartate transaminase(AST) more than 3 times of the normal upper limit, total bilirubin (TBIL) more than 2 times of the normal upper limit
Creatinine levels 1.5 mg/dL(132mol/L) for males and 1.4 mg/dL (123mol/L) for females or creatinine clearance 50 mL/min
History of malignant tumors
History of mental disorders
History of alcohol abuse or illegal drug abuse
Serious systemic disease which the investigators think would not be suitable for the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet